- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post administration - - Data presented at the…
- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) - - Patient reported…
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress - CAMBRIDGE, Mass.,…